Computational Insights into SARS-CoV-2 Main Protease Mutations and Nirmatrelvir Efficacy: The Effects of P132H and P132H-A173V-Reference-Cited by-同舟云学术

Computational Insights into SARS-CoV-2 Main Protease Mutations and Nirmatrelvir Efficacy: The Effects of P132H and P132H-A173V

Published:2024-06-24 Issue:13 Volume:64 Page:5207-5218
ISSN:1549-9596
Container-title:Journal of Chemical Information and Modeling
language:en
Short-container-title:J. Chem. Inf. Model.

Author:

Xia Yuan-Ling¹²^ORCID,Du Wen-Wen¹,Li Yong-Ping³,Tao Yan¹⁴,Zhang Zhi-Bi⁵,Liu Song-Ming¹,Fu Yun-Xin¹⁶,Zhang Ke-Qin¹,Liu Shu-Qun¹^ORCID

Affiliation:

1. State Key Laboratory for Conservation and Utilization of Bio-Resources in Yunnan & School of Life Sciences, Yunnan University, Kunming, Yunnan 650091, China

2. Editorial Office of Journal of Yunnan University (Natural Sciences Edition), Yunnan University, Kunming, Yunnan 650091, China

3. School of Agriculture, Yunnan University, Kunming, Yunnan 650091, China

4. Yunnan University Library, Yunnan University, Kunming, Yunnan 650091, China

5. Yunnan Key Laboratory of Stem Cell and Regenerative Medicine & Biomedical Engineering Research Center, Kunming Medical University, Kunming, Yunnan 650500, China

6. Human Genetics Center and Department of Biostatistics and Data Science, School of Public Health, The University of Texas Health Science Center, Houston, Texas 77030, United States

Funder

National Key Research and Development Program of China

State Key Laboratory for Conservation and Utilization of Bio-Resources, Yunnan University

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jcim.4c00334

Reference74 articles.

1. A new coronavirus associated with human respiratory disease in China

2. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

3. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

4. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

5. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab